GURUFOCUS.COM » STOCK LIST » USA » NAS » Biogen Inc (NAS:BIIB) » Definitions » Momentum Rank
Switch to:

Biogen (NAS:BIIB) Momentum Rank

: 1 (As of Today)
View and export this data going back to 1991. Start your Free Trial

Biogen has the Momentum Rank of 1.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Momentum Rank Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Biogen's Momentum Rank falls in comparison to its industry or sector. The grey bar indicates the Momentum Rank's extreme value range as defined by GuruFocus.



Biogen Momentum Rank Related Terms

Thank you for viewing the detailed overview of Biogen's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (NAS:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
Executives
Christopher Viehbacher director, officer: President and CEO C/O AXCELLA HEALTH, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Nicole Murphy officer: Head of Pharm Ops and Tech BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Rachid Izzar officer: Head of Alzheimer's Disease BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Jones William D /ca/ director
Maria C Freire director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Michael R Mcdonnell officer: EVP, Chief Financial Officer C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
Alphonse Galdes officer: EVP Pharmaceutical Oper & Tech BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Jesus B Mantas director BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Robin Kramer officer: VP, Chief Accounting Officer 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109
Daniel Karp officer: EVP, Corporate Development 225 BINNEY STREET, CAMBRIDGE MA 02142
Jeffrey D Capello officer: EVP & Chief Financial Officer C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Chirfi Guindo officer: EVP Glob. Mkt Acc & Cust Innov C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Ginger Gregory officer: EVP, Human Resources C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Jean-paul Kress officer: EVP Pres Int'l & Global Hd GTO 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142

Biogen (NAS:BIIB) Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership